Fox Chase Cancer Center | Strategic Alliance Partners

March 11, 2014

Elizabeth Plimack, MD, MS, attending physician, medical oncology, Fox Chase Cancer Center, discusses a phase I trial that looked at overcoming mTOR resistance with an HDAC inhibitor in renal cell carcinoma (RCC).

January 03, 2014

Antiangiogenic agents hold promise in gynecologic cancers, as evidenced by their single-agent activity in malignancies including ovarian cancer, recurrent endometrial cancer, and cervical cancer.

November 01, 2013

Robert A. Burger, MD, Professor, Department of Surgical Oncology, Director, Women's Cancer Center, Fox Chase Cancer Center, discusses the toxicity profile of bevacizumab when used to treat patients with ovarian cancer.

October 25, 2013

At the recent NCCN 8th Annual Congress on Hematologic Malignancies, Michael Millenson, MD, Fox Chase Cancer Center, discussed considerations in selecting second- and third-generation tyrosine-kinase inhibitors for the management of chronic myelogenous leukemia

October 09, 2013

Robert A. Burger, MD, FACOG, FACS, Professor, Department of Surgical Oncology, Director, Women's Cancer Center, Fox Chase Cancer Center, discusses the use of bevacizumab in patients with ovarian cancer.

December 05, 2011

Dr. Ranee Mehra from Fox Chase Cancer Center Discusses DNA Repair Enzymes

October 28, 2011

Dr. Lori Goldstein from Fox Chase Cancer Center on the Fox Chase Breast Evaluation Center

October 26, 2011

Dr. Lori Goldstein from Fox Chase Cancer Center on Fulvestrant in Metastatic Breast Cancer

September 28, 2011

Dr. Barbara Burtness from Fox Chase Cancer Center on the Head and Neck Symposium Design

September 27, 2011

Dr. Barbara Burtness from Fox Chase Cancer Center Discusses the Upcoming Head and Neck Cancer Symposium